OSOBIO PROMOTES BOB CASHMAN TO VICE PRESIDENT OF BUSINESS DEVELOPMENT

Sept. 18, 2012ALBUQUERQUE, N.M. – Robert "Bob" Cashman has been promoted to vice president of business development at OSO BioPharmaceuticals Manufacturing, LLC.

In his new role, Cashman is responsible for developing and executing strategies to expand the company's injectable pharmaceutical contract manufacturing business. He also will oversee existing and potential customer relationships, manage pricing structures, and direct strategic corporate alliances.

Cashman, who joined OsoBio in 2009, previously served as director of new business development for the company's East Coast market. He steps into a position vacated by Milton Boyer, who was appointed president of OsoBio in February.

"Bob has consistently demonstrated a keen ability to foster existing and new client opportunities for OsoBio," Boyer said. "As OsoBio continues to successfully grow as a CMO renowned for world-class customer care, project management and regulatory compliance, I know Bob will help us achieve the goals we've set for ourselves."

With more than 20 years of experience in contract pharmaceutical and biotechnology manufacturing, Cashman is a board member of the Philadelphia Drug Exchange, the oldest continually active trade organization in the United States. A member of the Parenteral Drug Association, he also heads the scholarship committee for the Drug, Chemical and Associated Technologies Association (DCAT). Cashman holds a bachelor's degree in business administration from Villanova University.

OsoBio is a contract manufacturing organization (CMO) that specializes in delivering injectable sterile liquid, suspension and lyophilized biologic and pharmaceutical products to the pharmaceutical industry. The company offers significant knowledge and experience in late phase clinical products and successfully taking them to commercialization. In the history of its Albuquerque, N.M., facility, OsoBio has manufactured more than 250 distinct commercial products in every major therapeutic category.

The U.S. Drug Enforcement Administration (DEA) has granted OsoBio registrations for Schedule II through V controlled substances.

Responsiveness, attention to detail and clear communication are the hallmarks of OsoBio's client care. Its employees are industry veterans who provide innovative solutions to clients' most difficult projects. To learn more, visit www.OsoBio.com.

Media contact: Karen Stinneford, 919.833.9102